Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
Sponsor: Novo Nordisk A/S
Summary
The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical management of participants. Data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. Baseline information/history will be recorded at time of switching from previous FVIII replacement therapy to turoctocog alfa from the enrolled participants and outcomes will be collected according to participants visit format.
Official title: Descriptive Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients - An Observational Retrospective Study
Key Details
Gender
MALE
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
900
Start Date
2024-11-10
Completion Date
2026-04-30
Last Updated
2026-02-13
Healthy Volunteers
No
Interventions
Turoctocog alfa
Turoctocog alfa was administered intravenously.
Locations (7)
National centre for Hamophilia
Baghdad, Iraq
Novo Nordisk Investigational Site
Baghdad, Iraq
Basrah Haemoplhilia centre
Basra, Iraq
Hilla Haemophilia centre
Hillah, Iraq
Karbala Haemophilia centre
Karbala, Iraq
Kirkuk Centre for Cancer and Blood Disorders
Kirkuk, Iraq
Najaf Haemophilia Centre
Najaf, Iraq